Ulcerative colitis (UC) is a chronic intestinal disease that affects millions worldwide. Current immunotherapies still fail in 40% of patients, highlighting the urgent need for alternative treatments that do not rely on immunosuppression. Our project aims to develop a live biotherapeutic product that through the production of secondary bile acids—bacterial metabolites with established benefits on mucosal healing and intestinal barrier integrity—would fill this existing gap in UC therapies.
- Field: Life Sciences
- Laboratory: Metabolic Signaling (SV-UPSCHOONJANS)
- Project leader: Antoine Jalil
- Budget: 52’500.00 CHF